ScreenerHero

MCRBSeres Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · serestherapeutics.com
4.560USD-2.56%Mkt Cap: 45.80M $P/E: —

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhanc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap45.80M $
Enterprise Value86.48M $
Revenue (TTM)1.88M $
Gross Profit-5.75M $
Net Income (TTM)5.70M $
Revenue/Share0.2020 USD
Last Price4.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees66
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.92
PEG—
EV/EBITDA-1.16
EV/Revenue45.93
P/S24.38
P/B1.30
EPS (TTM)-2.36
EPS (Forward)-4.95
52W Range
4.3751% of range29.98
52W High29.98 USD
52W Low4.375 USD
Profitability
Gross Margin-729.40%
Oper. Margin-2101.36%
EBITDA Margin0.00%
Profit Margin721.93%
ROE12.88%
ROA4.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF1.12M $
CapEx (TTM)252.00K $
FCF Margin-3430.74%
FCF Yield-141.04%
Net Debt41.05M $
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity1.88
Current Ratio2.11
Quick Ratio2.04
Book Value/Sh3.514 USD
Cash/Share1.569 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateApr 22, 2025
Analyst Consensus
Rating—
Target (Mean)17.00 USD
Upside (mean)+272.8%
Target Range12.00 USD – 22.00 USD
$12.00+272.8% to mean$22.00
# Analysts2
Ownership
Shares Out.10.04M
Float8.73M
Insiders11.49%
Institutions23.03%
Short Interest
Short Ratio3.1d
Short % Float4.11%
Short % Out.3.16%
Shares Short314.55K
Short (prev mo.)157.33K
Technical
SMA 505.757 (-20.8%)
SMA 20010.32 (-55.8%)
Beta0.21
S&P 52W Chg18.16%
Avg Vol (30d)78.79K
Avg Vol (10d)67.08K
Technical Indicators
RSI (14)37.9
MACD-0.3569
MACD Signal-0.3980
MACD Hist.+0.0411
BB Upper5.255 USD
BB Middle4.811 USD
BB Lower4.366 USD
BB Width18.47%
ATR (14)0.3766 USD
Vol Ratio (20d)0.73x